{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T04:27:41Z","timestamp":1793766461820,"version":"4.6.1"},"reference-count":54,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015742","name":"Forrest Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015742","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.clgc.2026.102628","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T15:47:30Z","timestamp":1785167250000},"page":"102628","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pre-therapeutic PSMA PET Imaging Biomarkers Demonstrate Prognostic Value in Patients Undergoing [177Lu]Lu-PSMA Therapy: A Systematic Review and Meta-analysis"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-8445-051X","authenticated-orcid":false,"given":"Kaylee","family":"Molin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0007-9401","authenticated-orcid":false,"given":"Suning","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel","family":"Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5101-6107","authenticated-orcid":false,"given":"Jeremy S.L.","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1273-5835","authenticated-orcid":false,"given":"Amir","family":"Iravani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8622-159X","authenticated-orcid":false,"given":"Michael S.","family":"Hofman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6636-8807","authenticated-orcid":false,"given":"Ghulam Mubashar","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6875-0719","authenticated-orcid":false,"given":"Martin A.","family":"Ebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6524-539X","authenticated-orcid":false,"given":"Jake","family":"Kendrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2026.102628_bib0001","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/j.1742-1241.2011.02799.x","article-title":"Characterising the castration\u2010resistant prostate cancer population: a systematic review","volume":"65","author":"Kirby","year":"2011","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.clgc.2026.102628_bib0002","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2026.102628_bib0003","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu] Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2026.102628_bib0004","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(22)00605-2","article-title":"PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu] Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial","volume":"23","author":"Buteau","year":"2022","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2026.102628_bib0005","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.eururo.2024.09.017","article-title":"Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)","volume":"87","author":"Gillessen","year":"2025","journal-title":"European Urology"},{"key":"10.1016\/j.clgc.2026.102628_bib0006","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.233460","article-title":"Quantitative 68Ga-PSMA-11 PET and clinical outcomes in metastatic castration-resistant prostate cancer following 177Lu-PSMA-617 (VISION trial)","volume":"312","author":"Kuo","year":"2024","journal-title":"Radiology"},{"key":"10.1016\/j.clgc.2026.102628_bib0007","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1470-2045(23)00529-6","article-title":"Overall survival with [177Lu] Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial","volume":"25","author":"Hofman","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2026.102628_bib0008","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/S1470-2045(25)00339-0","article-title":"Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial","volume":"26","author":"Emmett","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2026.102628_bib0009","doi-asserted-by":"crossref","first-page":"1583168","DOI":"10.3389\/fonc.2025.1583168","article-title":"Biomarkers to optimize PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer","volume":"15","author":"Beltran","year":"2025","journal-title":"Front Oncol"},{"key":"10.1016\/j.clgc.2026.102628_bib0010","article-title":"Determinants of outcome following PSMA-based radioligand therapy and mechanisms of resistance in patients with metastatic castration-resistant prostate cancer","volume":"15","author":"Kostos","year":"2023","journal-title":"Therap Adv Med Oncol"},{"key":"10.1016\/j.clgc.2026.102628_bib0011","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.clgc.2026.102628_bib0012","doi-asserted-by":"crossref","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","article-title":"Assessing bias in studies of prognostic factors","volume":"158","author":"Hayden","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clgc.2026.102628_bib0013","first-page":"746","article-title":"Repeatability of 68Ga-PSMA-HBED-CC PET\/CT\u2013derived total molecular tumor volume","volume":"63","author":"Seifert","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.clgc.2026.102628_bib0014","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.2967\/jnumed.119.236083","article-title":"Quantitative test\u2013retest measurement of 68Ga-PSMA-HBED-CC in tumor and normal tissue","volume":"61","author":"Pollard","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.clgc.2026.102628_bib0015","first-page":"14651858","volume":"4","author":"Chandler","year":"2019"},{"issue":"12","key":"10.1016\/j.clgc.2026.102628_bib0016","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.2967\/jnumed.125.270804","article-title":"Prognostic value of initial imaging and PSA change with [177Lu]Lu-PSMA-617 radiopharmaceutical therapy in patients with metastatic castration-resistant prostate cancer: a ProsTIC registry analysis","volume":"66","author":"Chen","year":"2025","journal-title":"J Nucl Med"},{"key":"10.1016\/j.clgc.2026.102628_bib0017","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2967\/jnumed.124.268167","article-title":"PET-Based TheraP eligibility and outcomes of VISION-eligible patients with metastatic castration-resistant prostate cancer who received (177)Lu-PSMA-617: importance of (18)F-FDG-avid discordant findings","volume":"66","author":"Demirci","year":"2025","journal-title":"J Nuc Med\u202f: Offi Publ Soci Nuc Med"},{"key":"10.1016\/j.clgc.2026.102628_bib0018","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1097\/RLU.0000000000004222","article-title":"Outcome of 177Lu-PSMA radionuclide treatment in advanced prostate cancer and its association with clinical parameters: a single-center experience","volume":"47","author":"Simsek","year":"2022","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.clgc.2026.102628_bib0019","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1007\/s00259-020-04723-z","article-title":"Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617","volume":"47","author":"Ferdinandus","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clgc.2026.102628_bib0020","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S1470-2045(21)00274-6","article-title":"Nomograms to predict outcomes after (177)Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study","volume":"22","author":"Gafita","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2026.102628_bib0021","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.2967\/jnumed.124.267723","article-title":"Initial experience with [177Lu] Lu-PSMA-617 after regulatory approval for metastatic castration-resistant prostate cancer: efficacy, safety, and outcome prediction","volume":"65","author":"Gafita","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.clgc.2026.102628_bib0022","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1007\/s00259-023-06281-6","article-title":"SUVmean on baseline [18F] PSMA-1007 PET and clinical parameters are associated with survival in prostate cancer patients scheduled for [177Lu] Lu-PSMA I&T","volume":"50","author":"Hartrampf","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"15","key":"10.1016\/j.clgc.2026.102628_bib0023","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.3390\/cancers16152670","article-title":"Analysis of molecular imaging and laboratory baseline biomarkers in PSMA-RLT: whole-body total lesion PSMA (TLP) predicts overall survival","volume":"16","author":"Hein","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.clgc.2026.102628_bib0024","author":"Huang","year":"2025","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.clgc.2026.102628_bib0025","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1007\/s00259-024-07003-2","article-title":"Prognostic (18)F-flotufolastat PET parameters for outcome assessment of (177)Lu-labeled PSMA-targeted radioligand therapy in metastatic castration-resistant prostate cancer","volume":"52","author":"Karimzadeh","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clgc.2026.102628_bib0026","article-title":"Bone matters: Ga-68 PSMA PET\/CT volumetrics predict PSA-PFS and OS in bone-dominant mCRPC patients treated with [177Lu]Lu-PSMA-617","author":"Kartal","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"24","key":"10.1016\/j.clgc.2026.102628_bib0027","doi-asserted-by":"crossref","first-page":"6155","DOI":"10.3390\/cancers14246155","article-title":"Single center experience with a 4-Week (177)Lu-PSMA-617 treatment interval in patients with metastatic castration-resistant prostate cancer","volume":"14","author":"Kemppainen","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.clgc.2026.102628_bib0028","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2967\/jnumed.122.264489","article-title":"Prognostic Value of Tumor Volume Assessment on PSMA PET After (177)Lu-PSMA Radioligand Therapy Evaluated by PSMA PET\/CT Consensus Statement and RECIP 1.0","volume":"64","author":"Kind","year":"2023","journal-title":"Journal of nuclear medicine\u202f: official publication, Society of Nuclear Medicine"},{"issue":"1","key":"10.1016\/j.clgc.2026.102628_bib0029","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3390\/cancers14010149","article-title":"Early PSA change after [177Lu]PSMA-617 radioligand therapy as a predicator of biochemical response and overall survival","volume":"14","author":"Kind","year":"2022","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.clgc.2026.102628_bib0030","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/ajco.14174","article-title":"Prognostic [68Ga]Ga-PSMA-11 PET biomarkers for [177Lu]Lu-PSMA radioligand therapy in metastatic castrate-resistant prostate cancer (Asian Population Study)","volume":"21","author":"Koh","year":"2025","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102628_bib0031","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.2967\/jnumed.125.270358","article-title":"Prognostic value of comprehensive analysis of metastatic prostate tumor changes from first to last [177Lu]Lu-PSMA therapy injections through serial high-speed whole-body 360degree cadmium-zinc-telluride SPECT","volume":"66","author":"Kunsch","year":"2025","journal-title":"J Nuc Med\u202f: Offi Publi Soci Nuc Med"},{"key":"10.1016\/j.clgc.2026.102628_bib0032","doi-asserted-by":"crossref","first-page":"560","DOI":"10.2967\/jnumed.121.262552","article-title":"(177)Lu-PSMA-617 and idronoxil in men with end-stage metastatic castration-resistant prostate cancer (LuPIN): patient outcomes and predictors of treatment response in a phase I\/II trial","volume":"63","author":"Pathmanandavel","year":"2022","journal-title":"J Nuc Med\u202f: Offi Publi, Soci Nuc Med"},{"key":"10.1016\/j.clgc.2026.102628_bib0033","doi-asserted-by":"crossref","first-page":"1538507","DOI":"10.3389\/fmed.2025.1538507","article-title":"Study of predictive factors for response to (177)LU-PSMA in patients with metastatic castration-resistant prostate cancer","volume":"12","author":"Peslier","year":"2025","journal-title":"Front Med"},{"key":"10.1016\/j.clgc.2026.102628_bib0034","article-title":"Radioligand treatment with [177Lu]Lu-PSMA I&T in elderly Patients - Safety, efficacy, and prognostic factors for survival","author":"Schwinger","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clgc.2026.102628_bib0035","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.2967\/jnumed.120.242057","article-title":"Semiautomatically quantified tumor volume using (68)Ga-PSMA-11 PET as a biomarker for survival in patients with advanced prostate cancer","volume":"61","author":"Seifert","year":"2020","journal-title":"J Nuc Med\u202f: Offi Publi Soci Nuc Med"},{"key":"10.1016\/j.clgc.2026.102628_bib0036","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1007\/s00259-020-05040-1","article-title":"PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177 Lu] Lu-PSMA-617 radioligand therapy in a bicentric analysis","volume":"48","author":"Seifert","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clgc.2026.102628_bib0037","doi-asserted-by":"crossref","first-page":"8143","DOI":"10.7150\/thno.60222","article-title":"Total tumor volume reduction and low PSMA expression in patients receiving Lu-PSMA therapy","volume":"11","author":"Seifert","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.clgc.2026.102628_bib0038","doi-asserted-by":"crossref","first-page":"7812","DOI":"10.7150\/thno.47251","article-title":"Analysis of PSMA expression and outcome in patients with advanced prostate cancer receiving (177)Lu-PSMA-617 radioligand therapy","volume":"10","author":"Seifert","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.clgc.2026.102628_bib0039","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1055\/s-0044-1779634","article-title":"Pretherapeutic PSMA PET-derived semiquantitative parameters as predictors of PSA response in patients with mCRPC Receiving [ (177) Lu]Lu-PSMA-617 radioligand therapy","volume":"34","author":"Siripongsatian","year":"2024","journal-title":"Indian J Radiol Imaging"},{"issue":"9","key":"10.1016\/j.clgc.2026.102628_bib0040","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1007\/s00259-025-07198-y","article-title":"Prognostic value of [18F]FDG- and PSMA-PET in patients evaluated for [177Lu]Lu-PSMA therapy of mCRPC","volume":"52","author":"Telli","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"10.1016\/j.clgc.2026.102628_bib0041","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.3390\/biomedicines10071575","article-title":"Baseline imaging derived predictive factors of response following [177Lu]Lu-PSMA-617 therapy in salvage metastatic castration-resistant prostate cancer: a lesion- and patient-based analysis","volume":"10","author":"van der Sar","year":"2022","journal-title":"Biomedicines"},{"issue":"12","key":"10.1016\/j.clgc.2026.102628_bib0042","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.3390\/cancers13122938","article-title":"PSMA expression predicts early biochemical response in patients with metastatic castration-resistant prostate cancer under [177Lu]Lu-PSMA-617 radioligand therapy","volume":"13","author":"Widjaja","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.clgc.2026.102628_bib0043","article-title":"Fully automated volumetric assessment of tumor burden using artificial intelligence on 68Ga-PSMA-11 PET predicts survival after 177Lu-PSMA therapy in metastatic castration-resistant prostate cancer","author":"Zang","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clgc.2026.102628_bib0044","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1097\/MNM.0000000000001611","article-title":"Response to [177Lu]Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients presenting with only lymph node metastases","volume":"43","author":"Zisser","year":"2022","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.clgc.2026.102628_bib0045","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/MNM.0000000000001539","article-title":"Prediction of early biochemical response after 177Lu-PSMA radioligand therapy with 68Ga-PSMA PET, a different perspective with quantitative parameters","volume":"43","author":"Aksu","year":"2022","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.clgc.2026.102628_bib0046","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1007\/s00259-023-06326-w","article-title":"Early biochemical and radiographic response after one cycle of [177Lu]Lu-PSMA I&T radioligand therapy in metastatic castration-resistant prostate cancer patients","volume":"50","author":"Cytawa","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clgc.2026.102628_bib0047","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.clgc.2018.09.014","article-title":"Results of a prospective phase 2 pilot trial of (177)Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer including imaging predictors of treatment response and patterns of progression","volume":"17","author":"Emmett","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2026.102628_bib0048","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s11307-024-01900-6","article-title":"Pre-treatment (68) Ga-PSMA-11 PET\/CT prognostic value in predicting response to (177)Lu-PSMA-I&T therapy and patient survival","volume":"26","author":"Eisazadeh","year":"2024","journal-title":"Mol Imaging Biol"},{"key":"10.1016\/j.clgc.2026.102628_bib0049","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2026.102628_bib0050","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.eururo.2025.08.005","article-title":"SPARC: the standardised prostate-specific membrane antigen positron emission tomography\/computed tomography analysis and reporting consensus: a Delphi analysis","volume":"89","author":"Herrmann","year":"2026","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2026.102628_bib0051","doi-asserted-by":"crossref","first-page":"226","DOI":"10.2967\/jnumed.121.261906","article-title":"Tumor sink effect in 68Ga-PSMA-11 PET: myth or reality?","volume":"63","author":"Gafita","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.clgc.2026.102628_bib0052","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41391-025-01034-y","article-title":"Prognostic factors of PSMA-targeted radioligand therapy in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis","volume":"29","author":"Yanagisawa","year":"2026","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.clgc.2026.102628_bib0053","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.2967\/jnumed.124.267789","article-title":"International benchmark for total metabolic tumor volume measurement in baseline 18F-FDG PET\/CT of lymphoma patients: a milestone toward clinical implementation","volume":"65","author":"Boellaard","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.clgc.2026.102628_bib0054","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13550-019-0572-z","article-title":"Evaluation of SUV normalized by lean body mass (SUL) in 68 Ga-PSMA11 PET\/CT: a bi-centric analysis","volume":"9","author":"Gafita","year":"2019","journal-title":"EJNMMI Res"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876732600128X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876732600128X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T04:16:48Z","timestamp":1793765808000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155876732600128X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":54,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S155876732600128X"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102628","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pre-therapeutic PSMA PET Imaging Biomarkers Demonstrate Prognostic Value in Patients Undergoing [177Lu]Lu-PSMA Therapy: A Systematic Review and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102628","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102628"}}